DR antigens influence graft outcome and HCV recurrence after liver transplantation.
Hepatitis C (HCV) recurrence following liver transplantation is universal. However, the severity of recurrence is highly variable between patients. We speculated that recipient DR antigens or the level of DR mismatching between the recipient and the donor might affect the severity of HCV recurrence and allograft survival. Clinical outcome was compared between HCV+ recipients with DR2, DR3, or DR5 versus HCV+ recipients with all other DR antigens. Recipients with DR3 had reduced allograft survival (P < .02), a higher rate of HCV recurrence (P < .05), and more severe liver disease (P < .05). Recipients with DR5 had superior allograft survival (P < .05), low rates of HCV recurrence (P < .05), and benign liver disease (P < .05). Clinical outcome of recipients with DR2 was equivalent (P = Ns) to the non-DR2, -3, -5 recipients. The incidence of acute rejection was equivalent (P = Ns) in all groups. The level of DR mismatching between donor and recipient did not affect HCV recurrence or severity. However, allograft survival was better (P < .05) in recipients with zero DR mismatches. The data show that host genetic factors play an important role in HCV recurrence and allograft outcome after liver transplantation. In addition, identification of DR antigens may help predict an HCV+ patient's relative risk for severe HCV recurrence.
Kimball
P
P
Medical College of Virginia Hospitals, Department of Transplant Surgery, Richmond, Virginia 23298, USA. pkimball@gems.vcu.edu
Stravitz
T
T
D004247:DNA / Q000235:genetics / Q000302:isolation & purification; D005787:Gene Frequency; D006085:Graft Survival / Q000276:immunology; D006684:HLA-DR Antigens / Q000235:genetics / Q000276:immunology*; D015802:HLA-DR2 Antigen / Q000235:genetics; D015803:HLA-DR3 Antigen / Q000235:genetics; D015805:HLA-DR5 Antigen / Q000235:genetics; D006526:Hepatitis C / Q000276:immunology* / Q000601:surgery; D006801:Humans; D016031:Liver Transplantation / Q000276:immunology*; D012008:Recurrence; D016896:Treatment Outcome
D006684:HLA-DR Antigens; D015802:HLA-DR2 Antigen; D015803:HLA-DR3 Antigen; D015805:HLA-DR5 Antigen; D004247:DNA